ATS/CDC/ERS/IDSA Clinical Practice Guidelines for Treatment of Drug-Resistant Tuberculosis: A Two-edged Sword?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

2 citing papers in PubMed.

1. A highly effective and inexpensive standardized treatment of multidrug-resistant tuberculosis: a multicenter prospective study in China.BMC infectious diseases · 2021
   Trial
2. The Reductionist Conundrum of an "Updated" Definition of Extensively Drug-Resistant Tuberculosis.American journal of respiratory and critical care medicine · 2021
   Article

Corrections and comments

• Commented on by
  Reply to Chang and Yew.2020
• Comment on
  Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline.2019

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as